Cite
Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
MLA
D’Arco, Alfonso Maria, et al. “Feasibility and Efficacy of Dose-Dense and Dose-Intense ABVD for High-Risk Patients with Advanced Hodgkin Lymphoma.” British Journal of Haematology, vol. 171, no. 4, Nov. 2015, pp. 662–65. EBSCOhost, https://doi.org/10.1111/bjh.13429.
APA
D’Arco, A. M., Califano, C., Barone, L., Belsito Petrizzi, V., Iovino, V., Langella, M., Maglione, V., Rivellini, F., & De Lorenzo, S. (2015). Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma. British Journal of Haematology, 171(4), 662–665. https://doi.org/10.1111/bjh.13429
Chicago
D’Arco, Alfonso Maria, Catello Califano, Lucia Barone, Valeria Belsito Petrizzi, Vincenzo Iovino, Maria Langella, Valentina Maglione, Flavia Rivellini, and Sonya De Lorenzo. 2015. “Feasibility and Efficacy of Dose-Dense and Dose-Intense ABVD for High-Risk Patients with Advanced Hodgkin Lymphoma.” British Journal of Haematology 171 (4): 662–65. doi:10.1111/bjh.13429.